Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
BACKGROUND: Obesity is a major public health issue, and new pharmaceuticals for weight management are needed. Therefore, we evaluated the efficacy and safety of the glucagon-like peptide-1 (GLP-1) analogue semaglutide in comparison with liraglutide and a placebo in promoting weight loss.
METHODS: We did a randomised, double-blind, placebo and active controlled, multicentre, dose-ranging, phase 2 trial. The study was done in eight countries involving 71 clinical sites. Eligible participants were adults (≥18 years) without diabetes and with a body-mass index (BMI) of 30 kg/m2 or more. We randomly assigned participants (6:1) to each active treatment group (ie, semaglutide [0·05 mg, 0·1 mg, 0·2 mg, 0·3 mg, or 0·4 mg; initiated at 0·05 mg per day and incrementally escalated every 4 weeks] or liraglutide [3·0 mg; initiated at 0·6 mg per day and escalated by 0·6 mg per week]) or matching placebo group (equal injection volume and escalation schedule to active treatment group) using a block size of 56. All treatment doses were delivered once-daily via subcutaneous injections. Participants and investigators were masked to the assigned study treatment but not the target dose. The primary endpoint was percentage weight loss at week 52. The primary analysis was done using intention-to-treat ANCOVA estimation with missing data derived from the placebo pool. This study is registered with ClinicalTrials.gov, number NCT02453711.
FINDINGS: Between Oct 1, 2015, and Feb 11, 2016, 957 individuals were randomly assigned (102-103 participants per active treatment group and 136 in the pooled placebo group). Mean baseline characteristics included age 47 years, bodyweight 111·5 kg, and BMI 39·3 kg/m2. Bodyweight data were available for 891 (93%) of 957 participants at week 52. Estimated mean weight loss was -2·3% for the placebo group versus -6·0% (0·05 mg), -8·6% (0·1 mg), -11·6% (0·2 mg),-11·2% (0·3 mg), and -13·8% (0·4 mg) for the semaglutide groups. All semaglutide groups versus placebo were significant (unadjusted p≤0·0010), and remained significant after adjustment for multiple testing (p≤0·0055). Mean bodyweight reductions for 0·2 mg or more of semaglutide versus liraglutide were all significant (-13·8% to -11·2% vs -7·8%). Estimated weight loss of 10% or more occurred in 10% of participants receiving placebo compared with 37-65% receiving 0·1 mg or more of semaglutide (p<0·0001 vs placebo). All semaglutide doses were generally well tolerated, with no new safety concerns. The most common adverse events were dose-related gastrointestinal symptoms, primarily nausea, as seen previously with GLP-1 receptor agonists.
INTERPRETATION: In combination with dietary and physical activity counselling, semaglutide was well tolerated over 52 weeks and showed clinically relevant weight loss compared with placebo at all doses.
Lanie Spaedy, MD @Dr_Lanie · 2014年12月29日 NYTimes: Diabetes Drug Gains Approval for Treatment of #Obesity (link: http://buff.ly/1trgC5S) buff.ly/1trgC5S Victoza renamed Saxenda to sell for weight loss
Denmark in New York @DenmarkinNY · 2015年1月27日 .@NovoNordisk puts 500 Saxenda reps on U.S. streets, aiming for $1B in weight-loss sales. (link: http://bit.ly/15LDt1y) bit.ly/15LDt1y
Dale Shepard MD, PhD @ShepardDale · 2015年7月2日 Study confirms weight loss With #Saxenda. Avg 12 lb loss and $12,000/yr. $1000/lb!! Diet/exercise are much cheaper. (link: http://www.medpagetoday.com/Endocrinology/Obesity/52408) medpagetoday.com/Endocrinology/…
Abd Tahrani @AbdTahrani · 4月30日 saxenda + intensive behavioural therapy (IBT) was superior to IBT only in terms of weight loss in #obesity . @EASOobesity #ECO2019 #obsmuk @hazlehurst_j
Linia Skin Clinic @liniaskinclinic · 7月14日 Saxenda can help adults with weight-related medical problems or obesity lose weight and keep the weight off. It should be used with a reduced-calorie meal plan and increased physical activity✨
Dr Andrew Suleh MD @andrewsuleh · 5月24日 , liraglutide, is already available in the type 2 diabetes drug Victoza at a maximum dose of 1.8 mg. While Victoza causes a bit of weight loss in many patients, the larger dose of liraglutide in Saxenda helps patients lose much more weight.